BioSpecifics Technologies Corp. Company Profile (NASDAQ:BSTC)

About BioSpecifics Technologies Corp. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. logoBioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BSTC
  • CUSIP: 09093110
  • Web: www.biospecifics.com
Capitalization:
  • Market Cap: $359.12 million
  • Outstanding Shares: 7,171,000
Average Prices:
  • 50 Day Moving Avg: $54.14
  • 200 Day Moving Avg: $52.55
  • 52 Week Range: $35.40 - $58.79
P/E:
  • Trailing P/E Ratio: 30.72
  • Foreward P/E Ratio: 25.95
  • P/E Growth: 1.34
Sales & Book Value:
  • Annual Revenue: $27.37 million
  • Price / Sales: 13.12
  • Book Value: $8.32 per share
  • Price / Book: 6.02
Profitability:
  • EBIDTA: $18.61 million
  • Net Margins: 43.13%
  • Return on Equity: 22.74%
  • Return on Assets: 19.88%
Debt:
  • Current Ratio: 21.57%
  • Quick Ratio: 21.57%
Misc:
  • Average Volume: 30,236 shs.
  • Beta: 1.31
  • Short Ratio: 5.08
 

Frequently Asked Questions for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

What is BioSpecifics Technologies Corp.'s stock symbol?

BioSpecifics Technologies Corp. trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies Corp.'s earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) announced its quarterly earnings data on Wednesday, March, 15th. The company reported $0.40 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.38 by $0.02. The firm earned $6.62 million during the quarter, compared to analysts' expectations of $6.76 million. BioSpecifics Technologies Corp. had a return on equity of 22.74% and a net margin of 43.13%. View BioSpecifics Technologies Corp.'s Earnings History.

Where is BioSpecifics Technologies Corp.'s stock going? Where will BioSpecifics Technologies Corp.'s stock price be in 2017?

2 brokers have issued 1-year target prices for BioSpecifics Technologies Corp.'s stock. Their forecasts range from $60.00 to $60.00. On average, they anticipate BioSpecifics Technologies Corp.'s share price to reach $60.00 in the next year. View Analyst Ratings for BioSpecifics Technologies Corp..

Are investors shorting BioSpecifics Technologies Corp.?

BioSpecifics Technologies Corp. saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 137,738 shares, an increase of 15.5% from the April 13th total of 119,218 shares. Based on an average daily trading volume, of 30,356 shares, the days-to-cover ratio is currently 4.5 days.

Who are some of BioSpecifics Technologies Corp.'s key competitors?

Who owns BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.92%), Dimensional Fund Advisors LP (3.45%), Vanguard Group Inc. (2.76%), Acadian Asset Management LLC (2.58%), Eagle Asset Management Inc. (2.53%) and Elk Creek Partners LLC (2.11%). Company insiders that own BioSpecifics Technologies Corp. stock include Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies Corp..

Who sold BioSpecifics Technologies Corp. stock? Who is selling BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, TFS Capital LLC, Morgan Stanley, Acadian Asset Management LLC, Royce & Associates LP, Schwab Charles Investment Management Inc., Eagle Asset Management Inc. and Northpointe Capital LLC. Company insiders that have sold BioSpecifics Technologies Corp. stock in the last year include Thomas Wegman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies Corp..

Who bought BioSpecifics Technologies Corp. stock? Who is buying BioSpecifics Technologies Corp. stock?

BioSpecifics Technologies Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Alliancebernstein L.P., Renaissance Technologies LLC, AQR Capital Management LLC, Dimensional Fund Advisors LP, ClariVest Asset Management LLC, Geode Capital Management LLC and Strs Ohio. View Insider Buying and Selling for BioSpecifics Technologies Corp..

How do I buy BioSpecifics Technologies Corp. stock?

Shares of BioSpecifics Technologies Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioSpecifics Technologies Corp. stock cost?

One share of BioSpecifics Technologies Corp. stock can currently be purchased for approximately $50.08.

Analyst Ratings

Consensus Ratings for BioSpecifics Technologies Corp. (NASDAQ:BSTC) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.00 (19.81% upside)

Analysts' Ratings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2016HC WainwrightReiterated RatingBuy$60.00N/AView Rating Details
8/10/2016Rodman & RenshawReiterated RatingBuy$60.00N/AView Rating Details
7/16/2015MLV & Co.Initiated CoverageBuy$76.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Earnings by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Earnings History by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017Q4 2016$0.38$0.40$6.76 million$6.62 millionViewN/AView Earnings Details
11/9/2016Q3 2016$0.41$0.42$6.95 million$6.88 millionViewListenView Earnings Details
8/9/2016Q216$0.35$0.35$6.25 million$6.20 millionViewN/AView Earnings Details
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details
11/10/2014Q314$0.19$0.20$4.00 million$4.00 millionViewN/AView Earnings Details
8/11/2014Q214$0.12$0.08$2.91 million$2.70 millionViewN/AView Earnings Details
5/8/2014Q114$0.07$0.11$2.46 million$2.80 millionViewN/AView Earnings Details
3/6/2014$0.17$0.25ViewN/AView Earnings Details
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Current Year EPS Consensus Estimate: $1.73 EPS
Next Year EPS Consensus Estimate: $1.93 EPS

Dividends

Dividend History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Insider Ownership Percentage: 23.19%
Institutional Ownership Percentage: 54.13%
Insider Trades by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Institutional Ownership by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Insider Trades by Quarter for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Thomas WegmanInsiderSell20,000$48.16$963,200.00View SEC Filing  
11/29/2016Toby WegmanDirectorSell10,000$48.08$480,800.00View SEC Filing  
9/15/2016Thomas WegmanInsiderSell3,100$41.21$127,751.00View SEC Filing  
9/13/2016Thomas WegmanInsiderSell3,605$37.55$135,367.75View SEC Filing  
9/2/2016Thomas WegmanInsiderSell9,201$37.53$345,313.53View SEC Filing  
8/30/2016Thomas WegmanInsiderSell4,299$37.54$161,384.46View SEC Filing  
8/24/2016Thomas WegmanPresidentSell4,173$38.08$158,907.84View SEC Filing  
8/23/2016Thomas WegmanPresidentSell4,100$38.60$158,260.00View SEC Filing  
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Latest Headlines for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Source:
DateHeadline
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 23 at 9:48 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : May 18, 2017
finance.yahoo.com - May 18 at 11:30 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:42 PM
americanbankingnews.com logo Brokerages Set $72.00 Price Target for BioSpecifics Technologies Corp. (BSTC)
www.americanbankingnews.com - May 12 at 11:20 AM
reuters.com logoBRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46
www.reuters.com - May 11 at 4:38 PM
finance.yahoo.com logoBioSpecifics posts 1Q profit
finance.yahoo.com - May 10 at 11:55 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 4:15 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 1:01 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:41 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Earns News Sentiment Rating of 0.50
www.americanbankingnews.com - May 3 at 3:46 PM
americanbankingnews.com logoPositive News Coverage Somewhat Likely to Affect BioSpecifics Technologies Corp. (BSTC) Stock Price
www.americanbankingnews.com - April 28 at 9:34 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp. (BSTC) Given $72.00 Average Price Target by Analysts
www.americanbankingnews.com - April 26 at 9:59 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Receiving Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 25 at 3:54 PM
finance.yahoo.com logoBiospecifics Technologies Corp. – Value Analysis (NASDAQ:BSTC) : April 21, 2017
finance.yahoo.com - April 21 at 4:10 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bullish Manner : BSTC-US : April 20, 2017
finance.yahoo.com - April 20 at 10:49 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
finance.yahoo.com - April 18 at 12:38 PM
americanbankingnews.com logoVery Positive News Coverage Somewhat Likely to Impact BioSpecifics Technologies Corp. (BSTC) Stock Price
www.americanbankingnews.com - April 18 at 9:28 AM
americanbankingnews.com logoFavorable Press Coverage Somewhat Likely to Effect BioSpecifics Technologies Corp. (BSTC) Share Price
www.americanbankingnews.com - April 13 at 4:17 PM
finance.yahoo.com logoETFs with exposure to Biospecifics Technologies Corp. : April 7, 2017
finance.yahoo.com - April 7 at 9:03 PM
finance.yahoo.com logoBiospecifics Technologies Corp. breached its 50 day moving average in a Bearish Manner : BSTC-US : April 7, 2017
finance.yahoo.com - April 7 at 4:02 PM
americanbankingnews.com logoZacks: BioSpecifics Technologies Corp. (BSTC) Given $72.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - April 6 at 10:15 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 9:22 PM
americanbankingnews.com logoZacks Investment Research Upgrades BioSpecifics Technologies Corp. (BSTC) to "Buy"
www.americanbankingnews.com - March 27 at 8:35 AM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 21 at 5:00 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 10:44 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:43 AM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 15 at 9:25 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 15 at 4:24 PM
americanbankingnews.com logoBioSpecifics Technologies Corp. (BSTC) to Release Earnings on Monday
www.americanbankingnews.com - March 10 at 9:36 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 8:54 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference
finance.yahoo.com - January 24 at 4:35 PM
streetinsider.com logoBiospecifics Technologies (BSTC) Reports Statistically Significant Results from Phase 2b Study of CCH in Patients with Cellulite
www.streetinsider.com - November 19 at 12:23 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
finance.yahoo.com - November 18 at 12:31 PM
finance.yahoo.com logoWill BioSpecifics Technologies (BSTC) Continue to Surge Higher?
finance.yahoo.com - November 18 at 12:31 PM
finance.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Financials
finance.yahoo.com - November 17 at 1:31 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - November 14 at 7:32 AM
seekingalpha.com logoBioSpecifics Technologies' (BSTC) Management on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 3:21 PM
biz.yahoo.com logoQ3 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open
biz.yahoo.com - November 9 at 1:04 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at Stifel 2016 Healthcare Conference
finance.yahoo.com - November 8 at 2:46 PM
biz.yahoo.com logoBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - November 7 at 3:35 PM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results on Wednesday, November …
finance.yahoo.com - November 2 at 3:39 PM
finance.yahoo.com logoBioSpecifics Technologies (BSTC) Catches Eye: Stock Up 5.2%
finance.yahoo.com - September 21 at 3:25 PM
finance.yahoo.com logoCan The Uptrend Continue for BioSpecifics Technologies (BSTC)?
finance.yahoo.com - September 20 at 9:52 AM
zacks.com logoFoamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7%
www.zacks.com - September 13 at 8:51 AM
zacks.com logoNew Strong Buy Stocks for September 7th
www.zacks.com - September 7 at 10:32 AM
finance.yahoo.com logoBioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
finance.yahoo.com - September 2 at 8:44 AM
zacks.com logoDipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
www.zacks.com - September 1 at 12:28 PM
finance.yahoo.com logoWhat Makes Collegium Pharmaceutical (COLL) a Strong Sell?
finance.yahoo.com - August 30 at 11:48 AM
zacks.com logoWeakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
www.zacks.com - August 29 at 3:20 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
finance.yahoo.com - August 29 at 3:20 PM

Social

Chart

BioSpecifics Technologies Corp. (BSTC) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff